Matthias Aizenberg

Matthias Aizenberg

Healthcare Innovation Consultant
Matthias Aizenberg is a seasoned expert in the Healthcare industry. He explores digital health, clinical processes, and healthcare management strategies. Matthias has a deep interest in pharmaceutical and healthcare innovation and is a well-trusted resource for biopharma professionals.
Evolving Trends and Innovations in Acute Coronary Syndrome Care
Management & Regulatory Evolving Trends and Innovations in Acute Coronary Syndrome Care

The field of acute coronary syndrome (ACS) care has witnessed significant advancements, driven by an evolving understanding of patient management practices and continuous clinical research efforts. These innovations encompass various aspects of treatment, from rethinking established protocols like

Worcestershire Trust Tackles Sepsis Data Challenges with EPR
Tech & Innovation Worcestershire Trust Tackles Sepsis Data Challenges with EPR

The Worcestershire Acute Hospitals NHS Trust recently faced significant hurdles in capturing real-time observations of sepsis patients through its electronic patient record (EPR) system. Sepsis, a potentially deadly medical emergency, necessitates swift treatment to prevent organ failure and death.

CROs Shift to Alternative Methods Following FDA Animal Testing Phase-Out
Research & Development CROs Shift to Alternative Methods Following FDA Animal Testing Phase-Out

Chinese contract research organization GemPharmatech has expanded its presence in the United States with a new facility in San Diego, announced on April 17. The facility is designed for laboratories and housing genetically engineered mouse models, aimed at enhancing their capabilities in offering

Is Columvi the Game-Changer for Refractory DLBCL Treatment?
Management & Regulatory Is Columvi the Game-Changer for Refractory DLBCL Treatment?

Roche's Columvi, a bispecific antibody known as glofitamab, has been approved by the European Commission (EC) for use in combination with gemcitabine and oxaliplatin (GemOx) to treat relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adults who are not candidates for autologous

Should We Bring Back Extinct Species? Lessons From Dire Wolves
Biotech & Bioprocessing Should We Bring Back Extinct Species? Lessons From Dire Wolves

Colossal Biosciences, a leading biotechnology and genetic engineering company, has announced a groundbreaking achievement: the resurrection of the dire wolf, which went extinct about 12,500 years ago. Founded in 2025, the company is also working on bringing back the woolly mammoth and has already

How Will INCOG's $75M Expansion Impact Sterile Injectables?
Biotech & Bioprocessing How Will INCOG's $75M Expansion Impact Sterile Injectables?

INCOG, a contract development and manufacturing organization (CDMO), recently made a substantial investment to expand its capabilities in the sterile injectables sector. In February 2024, the company committed $75 million to install an Optima syringe and cartridge filling line, projected to be GMP

HHS Layoffs and Reorganization Spark Opposition and Legal Action
Management & Regulatory HHS Layoffs and Reorganization Spark Opposition and Legal Action

The U.S. Department of Health and Human Services (HHS) is experiencing a turbulent phase marked by extensive layoffs and a major reorganization under Secretary Robert F. Kennedy Jr. These moves have ignited substantial controversy and legal battles, drawing sharp reactions from various stakeholders

ASU Study Uncovers Surprising Healing Mechanism in Necrotic Cells
Biotech & Bioprocessing ASU Study Uncovers Surprising Healing Mechanism in Necrotic Cells

A groundbreaking study from Arizona State University (ASU) has discovered remarkable insights about a potentially new healing process prompted by necrosis, the premature death of cells. This unexpected phenomenon, observed in fruit flies known for their regenerative capabilities, may have profound

How Is AI Revolutionizing Precision Medicine by 2029?
Management & Regulatory How Is AI Revolutionizing Precision Medicine by 2029?

The dramatic rise in the global AI in precision medicine market projects an impressive 25-30% surge by 2029. This rapid growth stems from numerous factors: breakthroughs in AI technology, escalating demand for personalized healthcare, the proliferation of genomic data, supportive government

How Will Landmark Bio Shape Artis Biosolutions' Future?
Biotech & Bioprocessing How Will Landmark Bio Shape Artis Biosolutions' Future?

Artis Biosolutions' acquisition of Landmark Bio marks a strategic move designed to bolster cell and gene therapy (CGT) manufacturing capabilities. Landmark Bio, founded by Harvard University, MIT, Fujifilm Diosynth Biotechnologies, Alexandria Real Estate Equities, and Cytiva, has been a key

Loading
Latest Articles

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later